IP Library Granted Patent US 9,056,154
Granted Patent B2
US 9,056,154 · App. 12/939,736 · Granted Jun 16, 2015

High-yield activation of polymer surfaces for covalent attachment of molecules

Inventors: Jeffrey Schwartz (Princeton, NJ); T. Joseph Dennes (Cranbury, NJ)
Assignee: The Trustees of Princeton University
A61L31/082A61L27/14A61L27/28A61L27/30A61L27/38A61L27/50A61L31/005C08H1/06C08J7/04C08J7/045C09J189/04C08J2379/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,056,154
App. No.
12/939,736
Granted
Jun 16, 2015
Kind
B2
Abstract

Polymer surfaces coated with organometallic layers, wherein the organometallic layers and polymer surfaces have functional groups that react to bond the organometallic layer to the polymer surface with organometallic functional groups remaining unreacted for the subsequent covalent attachment of organic overlayers. Coating methods and coated articles are also disclosed.

Claims (31)

1. A coated substrate comprising (a) a substrate comprising a polymer surface wherein the polymer is selected from the group consisting of polyamides, polyacrylamides, polyimides, polyurethanes, polyureas, polyamines, polyepoxides, polyesters, polysaccharides, polyethers, polyketones, polysulfonamides, polysulfides and copolymers of two or more thereof; (b) an organometallic coating bonded to said polymer surface comprising a polyalkoxide or a polydialkylamide of transition metal atoms selected from the group consisting of atoms of Group 4, Group 5 and Group 6 of the Periodic Chart; and (c) an organophosphorus, organocarboxylic acid or organocarboxylic acid ester compound overlayer coated on and covalently bonded to said organometallic layer.

2. The coated substrate of claim 1 , wherein the organo group of the organophosphorus, organocarboxylic acid or organocarboxylic acid ester overlayer compound is a saturated or unsaturated, substituted or unsubstituted alkyl group.

3. The coated substrate of claim 2 , wherein said alkyl group is substituted in the omega position and the omega-substituents of the omega-substituted organophosphorus, organocarboxylic acid or organocarboxylic acid ester overlayer compounds are selected from the group consisting of carboxylate, carbamate, hydroxyl, keto, ether, oxy, carbonate, amino, amide and thiol.

4. The coated substrate of claim 2 , further comprising a second overlayer of a biologically or pharmaceutically active compound covalently bonded to said organophosphorus, organocarboxylic acid or organocarboxylic acid ester compound overlayer.

5. The coated substrate of claim 1 , wherein said overlayer comprises an organophosphorus compound selected from the group consisting of phosphoric acids, phosphonic acids and phosphinic acids.

6. The coated substrate of claim 5 , wherein said organophosphorus overlayer comprises an organophosphoric acid compound or mixture of compounds of the structure:

(RO) x —P(O)—(OR′) y

wherein x is 1 or 2, y is 1 or 2 and x+y=3; R is a radical having a total of 1-30 carbons; where R′ is H, a metal or lower alkyl having 1-4 carbons; and, for at least a portion of the organo-phosphorus compounds in the overlayer, R′ is H.

7. The coated substrate of claim 5 , wherein said organophosphorus overlayer comprises an organophosphonic acid compound or mixture of compounds of the structure:

wherein x is 0 or 1, y is 1, z is 1 or 2 and x+y+z is 3; R and R″ are each independently radicals having a total of 1 to 30 carbons; R′ is H, a metal or lower alkyl having 1-4 carbons, and, for at least a portion of the organophosphorus compounds in the overlayer, R′ is H.

8. The coated substrate of claim 5 , wherein said organophosphorus overlayer comprises an organophosphinic acid compound or mixture of compounds of the structure:

wherein x is 0, 1 or 2, y is 0, 1 or 2, z is 1 and x+y+z is 3; R and R″ are each independently radicals having a total of 1 to 30 carbons; R′ is H, a metal or lower alkyl and, for at least a portion of the organophosphorus compounds in the overlayer, R′ is H.

9. The coated substrate of claim 1 , wherein said overlayer comprises an organophosphorus or organocarboxylic acid compound with an organo group containing a C 6 to C 18 hydrocarbon or substituted hydrocarbon group.

10. The coated substrate of claim 1 , wherein the substrate is a molded polymer article.

11. The coated substrate of claim 1 , wherein the polymer is in the form of a coating.

12. The coated substrate of claim 11 , wherein the polymer is a coating on an article made from another material selected from the group consisting of glass, silicon dioxide, metal, and another polymer.

13. The coated substrate of claim 1 , wherein said overlayer comprises a biologically or pharmaceutically active compound covalently bonded to the organometallic coating layer.

14. The coated substrate of claim 1 , wherein said overlayer comprises a biologically active ligand compound selected from cell attachment mediators or a substance selected from the group consisting of osteoinductive substances and substances that induce cellular growth, proliferation, and/or differentiation.

15. The coated substrate of claim 14 , wherein said biologically active ligand compound is selected from the group consisting of osteoinductive substances and substances that induce cellular growth and proliferation and integrin cell attachment mediators.

16. The coated substrate of claim 15 , wherein said biologically active ligand compound is selected from the group consisting of bone morphogenic proteins (BMP), epidermal growth factor (EGF), fibroblast growth factor (FGF), platelet-derived growth factor (PDGF), insulin-like growth factor (IGF-I and II), TGF-β and vascular endothelial growth factor (VEGF).

17. The coated substrate of claim 14 , wherein said osteoinductive substances comprise bone morphogenic proteins (BMP), and said substances that induce cellular growth comprise epidermal growth factor (EGF), fibroblast growth factor (FGF), platelet-derived growth factor (PDGF), insulin-like growth factor (IGF-I and II), TGF-β, and vascular endothelial growth factor (VEGF).

18. The coated substrate of claim 1 , wherein said overlayer comprises a pharmaceutically active compound selected from the group consisting of anti-neoplastic and anti-proliferative agents.

19. The coated substrate of claim 1 , wherein said overlayer comprises a active agent selected from the group consisting of acyclovir, cephradine, malphalen, tamoxifen, raloxifene, daunomycin, adriamycin, plumbagin, chlorambucil, ephedrine, atropine, quinine, digoxin, quinidine, biologically active peptides, chlorin e 6 , cephalothin, proline, proline analogues, penicillin V, aspirin, ibuprofen, steroids and nicotinic acid.

20. A polymer scaffold for tissue engineering comprising the coated substrate of claim 1 .

21. A polymer scaffold for tissue engineering comprising the coated substrate of claim 1 , wherein said overlayer comprises a biologically active ligand for cellular or tissue ingrowth.

22. The polymer scaffold of claim 21 , wherein said scaffold is adapted for the re-generation of nervous, musculo-skeletal, cartilaginous, tendenous, hepatic, pancreatic, ocular, integumentary, arterio-venous or urinary tissues or tissues forming solid or hollow organs.

23. The polymer scaffold of claim 21 , containing cells selected from the group consisting of cells of the muscular and skeletal systems, parenchymal cells, cells of intestinal origin, exocrine cells, bile duct cells, parathyroid cells, thyroid cells, cells of the adrenal-hypothalmic-pituitary axis, heart muscle cells, kidney epithelial cells, kidney tubular cells, kidney basement membrane cells, nerve cells, blood vessel cells, cells forming bone and cartilage, smooth muscle cells, skeletal muscle cells, ocular cells, integumentary cells, keratinocytes, skin cells and endothelial cells.

24. The polymer scaffold of claim 21 , wherein said cells are selected from the group consisting of chondrocytes, fibroblasts, osteocytes, osteoblasts, hepatocytes and pancreatic cells.

25. The polymer scaffold of claim 21 , containing cells selected from the group consisting of cells obtained from donors, embryonic stem cells, non-embryonic stem cells, cells from established cell culture lines, cells before genetic engineering and cells after genetic engineering.

26. An implantable medical device characterized by one or more surfaces comprising the coated substrate of claim 1 .

27. A method of regulating cellular attachment, migration and proliferation on a polymeric substrate, characterized by contacting living cells, tissues or biological fluids containing living cells with the polymer scaffold of claim 21 .

Assignments (2)
CONFIRMATORY LICENSE Recorded Jul 10, 2015
From: PRINCETON UNIVERSITY
To: NATIONAL SCIENCE FOUNDATION
Reel/Frame 036093/0134 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 4, 2011
From: SCHWARTZ, JEFFREY; DENNES, T. JOSEPH
To: THE TRUSTEES OF PRINCETON UNIVERSITY
Reel/Frame 025744/0544 →
Continuity (4)
Continuation 11677576 · Feb 21, 2007
Provisional Application 60775127 · Feb 21, 2006
Provisional Application 60804633 · Jun 13, 2006
Related Publication 20110110986A1 · May 12, 2011